Clinical Policy: Arimoclomol (Miplyffa)

Reference Number: PA.CP.PHAR.510
Effective Date: 02/2025
Last Review Date: 01/2025

Description
Arimoclomol (Miplyffa™) is a molecular chaperone activator of the heat-shock proteins.

FDA Approved Indication(s)
Miplyffa is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of PA Health & Wellness® that Miplyffa is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Niemann-Pick Disease Type C (must meet all)**:**

1. Diagnosis of NPC confirmed by one of the following (a or b):
   a. Genetic analysis indicating mutation in both alleles of *NPC1* or *NPC2*;
   b. Genetic analysis indicating mutation in one allele of *NPC1* or *NPC2*, along with one of the following (i or ii):
      i. Positive filipin staining test result;
      ii. Positive biomarker result (e.g., oxysterol, lyso-sphingolipid, bile acid);
2. Prescribed by or in consultation with a geneticist, neurologist, endocrinologist, or metabolic disease specialist;
3. Age ≥ 2 years;
4. Member presents with at least one neurological sign or symptom of the disease (*see Appendix D*);
5. Miplyffa is prescribed in combination with miglustat;
6. Miplyffa is not prescribed concurrently with Aqneursa™;
7. Dose does not exceed both of the following (a and b):
   a. 3 capsules per day;
   b. Any of following, based on body weight:
      i. For 8 kg to 15 kg: 141 mg per day;
      ii. For > 15 kg to 30 kg: 186 mg per day;
      iii. For > 30 kg to 55 kg: 279 mg per day;
      iv. For > 55 kg: 372 mg per day.

Approval duration: 6 months

B. Other diagnoses/indications
1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

II. Continued Therapy

A. Niemann-Pick Disease Type C (must meet all)**:**
1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.PHARM.01) applies;
2. Member is responding positively to therapy as evidenced by an improvement or stabilization in a domain affected by NPC (e.g., ambulation, fine motor skills, swallowing, sitting, speech);
3. Miplyffa is prescribed in combination with miglustat;
4. Miplyffa is not prescribed concurrently with Aqneursa;
5. If request is for a dose increase, new dose does not exceed both of the following (a and b):
   a. 3 capsules per day;
   b. Any of following, based on body weight:
      i. For 8 kg to 15 kg: 141 mg per day;
      ii. For > 15 kg to 30 kg: 186 mg per day;
      iii. For > 30 kg to 55 kg: 279 mg per day;
      iv. For > 55 kg: 372 mg per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2)**:**
1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.PHARM.01) applies.
   Approval duration: Duration of request or 12 months (whichever is less); or
2. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – PA.CP.PMN.53

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration
NPC: Niemann-Pick disease type C

Appendix B: Therapeutic Alternatives
Not applicable

Appendix C: Contraindications/Boxed Warnings
None reported
Appendix D: General Information

- Examples of neurological signs or symptoms of NPC include hearing loss, vertical supranuclear gaze palsy, dysarthria, ataxia, dystonia, impaired ambulation, dysarthria, dysphagia, seizures, and dementia.
- The ability to walk either independently or with assistance was an eligibility criterion for all patients in Miplyffa's pivotal trial. It is an objective measure of NPC neurological severity, and Miplyffa's efficacy evaluation was based on patients who were able to walk either independently or with assistance.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
NPC	Recommended dose, in combination with miglustat, based on actual body weight: • 8 kg to 15 kg: 47 mg PO TID • > 15 kg to 30 kg: 62 mg PO TID • > 30 kg to 55 kg: 93 mg PO TID • > 55 kg: 124 mg PO TID	372 mg/day

VI. Product Availability

Oral capsules: 47 mg, 62 mg, 93 mg, 124 mg

VII. References

1. Miplyffa Prescribing Information. Celebration, FL: Zevra Therapeutics, Inc.; September 2024. Available at https://miplyffa.com. Accessed November 5, 2024.
2. Mengel E, Patterson MC, Da Riol RM, et al. Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment. *J Inherit Metab Dis*. 2021;44(6):1463-1480. doi:10.1002/jimd.12428
3. Geberhiwot T, Moro Alessandro, Dardis A, et al. Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet Journal of Rare Diseases 2018 April 6;13(1):50. Patterson MC, Clayton P, Gissen P, et al. Recommendations for the detection and diagnosis of Niemann-Pick disease type C: An update. Neurol Clin Pract. 2017;7(6):499-511.

Reviews, Revisions, and Approvals	Date
Policy created	01/2025